AUA Annual Meeting Highlights: Bladder Cancer (2017)

As per the National Cancer Institute, there will be an estimated 79,960 new cases of bladder cancer with an estimated 14,240 deaths in 2016.1 With a workforce of approximately 11,990 practicing urologists in the United States, it is imperative that every urologist understand how to treat this cancer.
 

 

Target Audience

  • Urologists
  • Urologists in training
  • Non-physician providers involved in urology

Learning Objectives

Course 002IC: Chemotherapy and Immunotherapy Options for Genitourinary Malignancies
Learning Objectives:
At the conclusion of this CME activity, participants should be able to:

  • Obtain familiarization with standard of care chemotherapy regimens for genitourinary malignancies
  • Obtain familiarization with newer immunotherapy options in the treatment of genitourinary malignancies
  • Enhance the identification and management of toxicities with relation to these agents
  • Identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies


Course 017IC: AUA Guidelines 2017: Non-Muscle Invasive Bladder Cancer
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Analyze the latest evidence on the management of non-muscle invasive bladder cancer as outlined in the AUA guidelines
  • Improve the therapeutic decision making processes by illustrating the application of these guidelines in urological practice
  • Acquire in-depth knowledge on the process by which evidence is used to develop scientifically rigorous, yet actionable, guidelines

 

Course 056IC: Difficult Cases in High Risk Bladder Cancer: An Evidence Based Approach 
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Apply clinical guidelines and level 1 evidence to their own practices in high risk bladder cancer
  • Extrapolate from the practice guidelines to deal with unique situations not covered by the guidelines
  • Appraise the available literature on high risk bladder cancer

 

Course 075IC: AUA/ASCO/ASTRO/SUO Guidelines 2017: Muscle Invasive Bladder Cancer
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Analyze the latest evidence on the management of muscle invasive bladder cancer as outlined in the AUA guidelines
  • Improve the diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice
  • Acquire in-depth knowledge on the process by which evidence is used to develop scientifically rigorous, yet actionable, guidelines

 

Course 085IC: Management of Nonmuscle Invasive Bladder Cancer: Practice Solutions for Common Problems
Learning Objectives
At the conclusion of this CME activity, participants should be able to:

  • Implement the 2015 practice guidelines into the office setting
  • Identify the best intravesical agent and duration of therapy for low, intermediate, and high risk settings
  • Identify methods to treat significant toxicities from various intravesical therapies
  • Define high risk scenarios that necessitate cystectomy
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Course opens: 
10/11/2017
Course expires: 
10/11/2018
Rating: 
0

Course 002IC: Chemotherapy and Immunotherapy Options for Genitourinary Malignancies
Costas D. Lallas, MD, FACS, Course Director
Vice Chair and Professor of Urology
Thomas Jefferson University Hospital
Philadelphia, PA
Disclosures: Nothing to disclose
 
Anne E. Calvaresi, MSN, CRNP
Nurse Practitioner, Urologic Oncology
Thomas Jefferson University
Philadelphia, PA
Disclosures: Nothing to disclose
 
Edouard J. Trabulsi, MD, FACS
Professor and Vice Chair, Department of Urology
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, PA
Disclosures: Centocor: Consultant or Advisor, Meeting Participant or Lecturer; Amgen: Consultant or Advisor, Meeting Participant or Lecturer; Dendreon: Consultant or Advisor, Meeting Participant or Lecturer; Medivation: Consultant or Advisor, Meeting Participant or Lecturer; Photocure: Consultant or Advisor; GenomeDx: Consultant or Advisor
 
Course 017IC: AUA Guidelines 2017: Non-Muscle Invasive Bladder Cancer
Sam Chang, MD, MBA, Course Director
Oncology Fellowship Director
Vice-Chair of Urologic Surgery
Vanderbilt University Medical Center
Nashville, TN
Disclosures: ENDO: Scientific Study or Trial; Janssen: Consultant or Advisor, Meeting Participant or Lecturer; Dendreon: Consultant or Advisor; Amgen: Consultant or Advisor; Allergan: Consultant or Advisor; GE Health Services: Consultant or Advisor; Predictive Bioscience: Consultant or Advisor; Astellas: Consultant or Advisor; Predictive Biosciences: Consultant or Advisor; Dendreon: Consultant or Advisor; ENDO: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc: Scientific Study or Trial; Cepheid: Scientific Study or Trial; GLG: Consultant or Advisor; Bayer: Consultant or Advisor; Janssen: Consultant or Advisor; Tolmar: Consultant or Advisor; Janssen: Consultant or Advisor; tolmar: Consultant or Advisor
 
James McKiernan, MD
Professor and Chairman, Department of Urology
Columbia University
New York, NY
Disclosures: Sanofi-Aventis: Meeting Participant or Lecturer; Astellas oncology: Meeting Participant or Lecturer; Sanofi: Meeting Participant or Lecturer; Sanofi Aventis: Scientific Study or Trial; Exosome Diagnostics: Scientific Study or Trial
 
Chad Ritch, MD, MBA
Assistant Professor of Urology
University of Miami, Miller School of Medicine
Miami, FL
Disclosures: Nothing to disclose
 
Course 056IC: Difficult Cases in High Risk Bladder Cancer: An Evidence Based Approach 
Michael Cookson, MD, MMHC, FACS, Course Director
Professor and Chair, Department of Urology
University of Oklahoma
Oklahoma City, OK
Disclosures: Endo: Consultant or Advisor, Scientific Study or Trial; Spectrum: Consultant or Advisor; GE Healthcare: Consultant or Advisor, Scientific Study or Trial; Myriad: Consultant or Advisor; US HIFU: Consultant or Advisor; Covidien: Consultant or Advisor, Scientific Study or Trial; Photocure: Meeting Participant or Lecturer; Myriad: Consultant or Advisor; Astellas/Medivation: Meeting Participant or Lecturer; PersonalizeDx, an Abbott Company: Consultant or Advisor; Sanofi US Services, Inc.: Consultant or Advisor; Janssen: Meeting Participant or Lecturer; Bayer: Meeting Participant or Lecturer, Scientific Study or Trial; MDxHealth, INc.: Consultant or Advisor; Bayer HealthCare LLC: Consultant or Advisor; Astellas: Consultant or Advisor; Altor Bioscience Cooperation: Consultant or Advisor; Photocure: Consultant or Advisor; TesoRx Pharma LLC: Consultant or Advisor; MDx Health: Consultant or Advisor; MDxHealth: Consultant or Advisor; Janssen Biotech, Inc.: Consultant or Advisor; CiCloMed: Consultant or Advisor; Altor Bioscience Corp.: Consultant or Advisor; Photocure: Meeting Participant or Lecturer, Scientific Study or Trial; Takeda Pharmaceutical: Meeting Participant or Lecturer; Myovant Sciences: Consultant or Advisor; Genomic Health: Consultant or Advisor; MDxHealth: Consultant or Advisor; Pacific Edge Diagnostics USA: Consultant or Advisor
 
Jeffrey Holzbeierlein, MD
Director, Urologic Oncology
Interim Chair, Department of Urology
University of Kansas Health System
Kansas City, KS
Disclosures: Endo Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Ferring: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Consultant or Advisor, Meeting Participant or Lecturer; Amgen: Meeting Participant or Lecturer; medivation: Consultant or Advisor; MDx Health: Scientific Study or Trial
 
Timothy Masterson, MD
Associate Professor, Department of Urology
Indiana University School of Medicine
Indianapolis, IN
Disclosures: Nothing to disclose
 
Dr. Hristos Kaimakliotis, MD
Assistant Professor of Urology
Indiana University School of Medicine
Disclosures: Nothing to disclose
 
Course 075IC: AUA/ASCO/ASTRO/SUO Guidelines 2017: Muscle Invasive Bladder Cancer
Jeffrey Holzbeierlein, MD, Course Director
Director, Urologic Oncology
Interim Chair, Department of Urology
University of Kansas Health System
Kansas City, KS
Disclosures: Endo Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Ferring: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Consultant or Advisor, Meeting Participant or Lecturer; Amgen: Meeting Participant or Lecturer; medivation: Consultant or Advisor; MDx Health: Scientific Study or Trial
 
Jonathan Rosenberg, MD
Associate Member and Section Head, Genitourinary Oncology Service
Associate Attending Physican
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Merck: Consultant or Advisor, Investment Interest; Oncogenex: Consultant or Advisor, Scientific Study or Trial; Onyx: Consultant or Advisor; Uptodate.com: Health Publishing; Bladder Cancer Advocacy Network: Leadership Position; Boehringer Ingelheim: Consultant or Advisor; Bristol-Myers Squibb: Consultant or Advisor, Scientific Study or Trial; Dendreon: Consultant or Advisor; Eli Lilly: Consultant or Advisor; Genentech: Consultant or Advisor, Scientific Study or Trial; Illumina: Investment Interest; Astellas: Scientific Study or Trial; NCI Bladder Cancer Task Force: Leadership Position; Alliance for Clinical Trials in Oncology: Leadership Position; Mirati: Scientific Study or Trial; Sanofi US Services: Consultant or Advisor; Agensys: Consultant or Advisor, Scientific Study or Trial; AstraZeneca: Consultant or Advisor, Meeting Participant or Lecturer; Bayer: Consultant or Advisor; Bristol-Myers Squibb: Consultant or Advisor, Meeting Participant or Lecturer; EMD Serono: Consultant or Advisor; Inovio: Consultant or Advisor; Medscape: Meeting Participant or Lecturer; Seattle Genetics: Consultant or Advisor; Gritstone: Consultant or Advisor
 
Jeff Michalski, MD, MBA, FACR, FASTRO
Vice Chairman, Radiation Oncology
Washington University Medical School
St. Louis, MO
Disclosures: Nothing to disclose
 
Course 085IC: Management of Nonmuscle Invasive Bladder Cancer: Practice Solutions for Common Problems
Cheryl Lee, MD, Course Director
Chair, Department of Urology
The Ohio State University
Columbus, OH
Disclosures: Adolor: Health Publishing; Pfizer: Scientific Study or Trial; Tengion, Inc: Consultant or Advisor, Scientific Study or Trial; Endo Pharmaceuticals: Scientific Study or Trial; Inverness: Consultant or Advisor; Photocure: Health Publishing; Allergan: Health Publishing, Consultant or Advisor; Archimedes: Consultant or Advisor; CVI: Consultant or Advisor; MedEdicus: Health Publishing
 
Ashish M. Kamat, MBBS, MD, FACS
Professor of Urology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Biosite: Scientific Study or Trial; Endo Pharmaceuticals: Scientific Study or Trial; Bioniche Therapeutics: Scientific Study or Trial; Adolor: Scientific Study or Trial; Celgene: Scientific Study or Trial; Tetralogic Pharmaceuticals: Consultant or Advisor; Astra-Zeneca: Scientific Study or Trial; Precision Therapeutics: Consultant or Advisor; GE Healthcare: Meeting Participant or Lecturer; Taris Biomedical: Consultant or Advisor; Archimedes, Inc.: Consultant or Advisor; Alere, Inc.: Scientific Study or Trial; FKD: Scientific Study or Trial; Photocure: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Sanofi: Consultant or Advisor, Meeting Participant or Lecturer; Cubist: Meeting Participant or Lecturer; Allergan: Meeting Participant or Lecturer; Abbott Molecular: Consultant or Advisor; Theralase: Consultant or Advisor; Telesta Therapeutics Inc. (formerly Bioniche): Consultant or Advisor; Heat Biologics: Consultant or Advisor, Scientific Study or Trial; Pacific Edge, Ltd: Meeting Participant or Lecturer; Merck: Consultant or Advisor, Scientific Study or Trial; Aurasence: Consultant or Advisor; Adolor: Consultant or Advisor, Scientific Study or Trial; Spectrum Pharmaceuticals: Consultant or Advisor; Oncogenix: Consultant or Advisor; Cepheid: Consultant or Advisor
 
J. Alfred Witjes, MD
Professor, Oncological Urology
Radboud University Medical Center
Nijmegen, Netherlands
Disclosures: Photocure Oslo: Meeting Participant or Lecturer; MEL: Consultant or Advisor, Meeting Participant or Lecturer; Sanofi Pasteur: Consultant or Advisor, Meeting Participant or Lecturer; Spectrum: Consultant or Advisor, Meeting Participant or Lecturer; Taris: Consultant or Advisor, Meeting Participant or Lecturer; Aestellas: Consultant or Advisor, Meeting Participant or Lecturer; ENDO Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer; GE healthcare: Consultant or Advisor, Meeting Participant or Lecturer; Ipsen: Meeting Participant or Lecturer; Theracoat: Consultant or Advisor, Scientific Study or Trial
 
Kamal S. Pohar, MD
Associate Professor of Urology
The Ohio State University
Columbus, OH
Disclosures: Nothing to disclose
 
Planner Disclosures
Education Council
Manoj Monga, MD, FACS
Director, Center for Endourology & Stone Disease
Cleveland Clinic
Cleveland, OH
Disclosures: US Endoscopy: Consultant or Advisor; Thermadex: Consultant or Advisor; Percuvision: Consultant or Advisor; Histosonics: Consultant or Advisor; Taris Biomedical: Scientific Study or Trial; Xenolith: Scientific Study or Trial; Cook Urological: Meeting Participant or Lecturer; Mission Pharmacal: Meeting Participant or Lecturer; Coloplast: Consultant or Advisor; Olympus: Consultant or Advisor; Bard: Consultant or Advisor; Fortec: Other: Quality Assurance; Endourology Society: Leadership Position; Indian American Urological Association: Leadership Position; Ohio Urological Society: Leadership Position; Journal of Endourology: Health Publishing; Indian Journal of Urology: Health Publishing; Brazilian Journal of Urology: Health Publishing; Practical Reviews in Urology: Health Publishing; CMS SCIP - Representative for AUA: Leadership Position
 
Victor W. Nitti, MD
Professor, Department of Urology
Professor, Department of Obstetrics and Gynecology
Director, Female Pelvic Medicine and Reconstructive Surgery
Vice Chair, Department of Urology
NYC School of Medicine
New York, NY
Disclosures: Astellas: Health Publishing, Scientific Study or Trial; Ethicon: Consultant or Advisor; Allergan: Health Publishing, Scientific Study or Trial; Medtronic: Consultant or Advisor; Allergan: Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Pfizer: Health Publishing, Consultant or Advisor; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Uroplasty: Consultant or Advisor; American Medical Systems: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Astellas: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Pfizer: Consultant or Advisor; Ipsen: Consultant or Advisor; Ono: Consultant or Advisor; Theracoat: Consultant or Advisor; Pneumoflex: Consultant or Advisor; Pfizer: Consultant or Advisor; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial
 
Brant Inman, MD, MS
Associate Professor, Surgery
Vice Chief, Urology
Duke Cancer Institute of Duke University
Durham, NC
Disclosures: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Ferring Pharmaceuticals: Consultant or Advisor; Genentech Inc: Scientific Study or Trial; Pfizer: Other: Sponsored educational forum; Combat Medical: Consultant or Advisor, Scientific Study or Trial; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor; AstraZeneca: Consultant or Advisor; BioCancell: Consultant or Advisor; Nucleix: Scientific Study or Trial

Method of Participation
To claim CME credit/hours of participation, the learner must read the overview of courses 002IC, 017IC, 056IC, 075IC, and 085IC, complete the posttest, passing with 80% accuracy and submit the evaluation.
 
Estimated time to complete this activity: 1.25 hours
 
Release Date: October 2017
Expiration Date: October 2018


Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Credit Designation
The American Urological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.
 
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
 
This enduring material credit is valid only for content reformatted from courses 002IC, 017IC, 056IC, 075IC, and 085IC.
 
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
 
AUA Disclosure Policy 
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
 
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
 

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

 
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
 
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Acknowledgements
The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:

Merck
 
Reproduction Permission
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
 
AUA Privacy and Confidentiality Policy
www.auanet.org/education/confidentiality-statement.cfm
 
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
 
CME Information
For all inquiries regarding CME credit email: education@AUAnet.org

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Please login or register to take this course.